Skip to content
★ Sign in to follow
GI

GeneMatrix Inc. Stock: price and insider trades · South Korea

진매트릭스

KR·Mcap ₩31.7BHealth Care

No insider purchase over the last 90 days. The latest, by 홍선표, was filed 20 Jul 2026.

GeneMatrix Inc.: what insiders have been doing

This page follows insider dealings at GeneMatrix Inc. as filed with DART (FSS), a company from the Health Care sector. 4 insiders have disclosed 8 filings since 10 November 2025.

The flow runs one way only: 3 insiders bought (7 purchases) and nobody sold on the market. The totals do not cover 7 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 senior executives and 1 chief executive.

The last purchase on record was published on 23 July 2026, which is 110 days ago.

Across the 2,630 companies tracked on its exchange, the median is 7 filings; at 8 filings, this issuer sits above that mark. Looking back to 2022, when coverage begins, insiders filed 8 purchases and no sales.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.

Insider Decl.
13
Thresholds
n/a
Buy Volume
n/a
8 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
김석준2 buys
김수옥2 buys
홍선표2 buys
Fundamental score
Ranked 18,936 of 26,911 companies
37.9
score / 100
Value
41
Quality
35
FCF yld4.7%
Earn yld-7.0%
EV/EBITDA·
ROE-16%
Gross mgn59%
Net mgn-17%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩1,588
Analyst consensus
·
Income statement
Revenue₩10.6B
Gross profit₩6.3B59% margin
EBITDA-₩1.2B-11% margin
Net income-₩1.8B-44.3% margin
Valuation
Beta1.04
Balance sheet & cash
Market cap₩31.7B
Total debt₩3.7B
Free Cash Flow₩1.2B
Debt / Equity70%
Profitability & ownership
ROE-15.6%
ROA-6.0%
% insiders16.0%
% institutions0.3%
Last declaration on 20 July 2026
Declarations14 total
  • Other
    Other(filed)
    0DART
  • ▲
    부사장Executives(filed)
    0DART
    1,466 sharesShareKRXDART:20260720000052
    Canonical exit: 18 Oct 2026 (T+90)
  • ▲
    Executives
    0DART
    4,570 sharesShareKRXDART:20260710000039
    Canonical exit: 4 Oct 2026 (T+90)
  • ▲
    Executives
    0DART
    5,100 sharesShareKRXDART:20260709000147
    Canonical exit: 4 Oct 2026 (T+90)
  • ▲
    Executives
    0DART
    3,240 sharesShareKRXDART:20260702000185
    Canonical exit: 27 Sept 2026 (T+90)
  • ▲
    Executives
    0DART
    687 sharesShareKRXDART:20260702000156
    Canonical exit: 27 Sept 2026 (T+90)
  • ▲
    Executives
    0DART
    3,700 sharesShareKRXDART:20260702000141
    Canonical exit: 24 Sept 2026 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    Executives
    0DART
    11,051 sharesShareKRXDART:20230927000538
    Canonical exit: 25 Dec 2023 (T+90)
  • ▲
    Executives
    0DART
    10,000 sharesShareKRXDART:20230926000062
    Canonical exit: 25 Dec 2023 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART

14 of 14 declarations

About GeneMatrix Inc.

진매트릭스 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in developing innovative solutions for the medical sector.